cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Seagen Inc
18 own
15 watching
Current Price
$218.33
$2.53
(1.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
36,468.91M
52-Week High
52-Week High
219.39000
52-Week Low
52-Week Low
117.09000
Average Volume
Average Volume
2M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
53.0987
iconMarket Capitalization36,468.91M
icon52-Week High219.39000
icon52-Week Low117.09000
iconAverage Volume2M
iconDividend Yield--
iconP/E Ratio53.0987
What does the Seagen Inc do?
Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML); ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL. In addition, it is involved in developing SEA-CD40 that is in Phase I clinical trial for patients with solid tumors and hematologic malignancies; SGN-CD19B, which is in Phase I clinical trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; SGN-CD123A that is in Phase I trial for patients with relapsed or refractory AML; SGN-CD352A, which is in Phase I clinical trial for patients with relapsed or refractory multiple myeloma; SGN-2FF that is in Phase I clinical trial for patients with advanced solid tumors; and ASG-15ME that is in Phase I clinical trial for patients with urothelial cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; and Unum Therapeutics, Inc., as well as has co-development agreement with Agensys, Inc. and Genmab A/S. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Read More
How much money does Seagen Inc make?
News & Events about Seagen Inc.
Business Wire
5 months ago
Seagen Inc. (NASDAQ: SGEN) today announced an update to the U.S. Prescribing Information (PI) for ADCETRIS (brentuximab vedotin) to include six-year overall survival results from the phase 3 ECHELON-1 clinical trial of ADCETRIS plus combination chemotherapy in patients with previously untreated...
Zolmax
5 months ago
Avoro Capital Advisors LLC lifted its stake in shares of Seagen Inc. (NASDAQ:SGEN Get Rating) by 1.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,885,000 shares of the biotechnology companys stock after purchasing an additional 20,000 shares during ...
Business Wire
5 months ago
Seagen Inc. (NASDAQ: SGEN) today announced updated efficacy and safety results from Part C of a phase 2 single-arm trial (SGN35-027) evaluating the antibody-drug conjugate ADCETRIS (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin...
Globe Newswire
7 months ago
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased ...
Zolmax
7 months ago
Seagen Inc. (NASDAQ:SGEN Get Rating) SVB Leerink increased their FY2024 earnings per share estimates for Seagen in a research report issued to clients and investors on Tuesday, April 25th. SVB Leerink analyst A. Berens now anticipates that the biotechnology company will post earnings of $0.34 per ...
Frequently Asked Questions
Frequently Asked Questions
What is Seagen Inc share price today?
plus_minus_icon
Can Indians buy Seagen Inc shares?
plus_minus_icon
How can I buy Seagen Inc shares from India?
plus_minus_icon
Can Fractional shares of Seagen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Seagen Inc stocks?
plus_minus_icon
What is today’s traded volume of Seagen Inc?
plus_minus_icon
What is today’s market capitalisation of Seagen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Seagen Inc?
plus_minus_icon
What percentage is Seagen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Seagen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$218.33
$2.53
(1.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
$0.38
$-0.00 (-0.53 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$310.18
$-0.55 (-0.18 %)
Emergent BioSolutions Inc
Emergent BioSolutions Inc
$2.42
$-0.11 (-4.35 %)
Bio-Techne Corp.
Bio-Techne Corp.
$68.05
$2.01 (3.04 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
$0.38
$-0.00 (-0.53 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$310.18
$-0.55 (-0.18 %)
Emergent BioSolutions Inc
Emergent BioSolutions Inc
$2.42
$-0.11 (-4.35 %)
Bio-Techne Corp.
Bio-Techne Corp.
$68.05
$2.01 (3.04 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00